Image SHA-256 — or-parkinsons-mech.png
f3161c614a7829e8138798207dae315b58f8608a6d64056e27d35605db45b71a
Licensed Research: Parkinson's Mechanism Analysis
$42.5K
In stock
SKU
OR-PARKINSONS-MECH
Leave blank to use the product price.
Computational research findings on the elemental signatures correlated with Parkinson's disease biology. Licensed transfer; patent-pending; not medical advice; not a cure.
First to market
Publicly online since 2010 · U.S. patent applications since 2012 · inventions offered since 2014. The work of Christopher Gabriel Brown, independently documented.
First posted:
·
Last updated:
This item is delivered by Christopher Gabriel Brown by email within 24 hours of your order. You'll receive the deliverable at the email on your order. USA delivery only. Founder Access Pass credit (code FAP99CREDIT) applies at checkout automatically.
Licensed Research · Alchemy Data V2 Elemental Discovery · Patent-pending · USA only
License fee
$42,500.00 USD — Licensed transfer to a named USA buyer entity.
License terms (IP-retained model)
A purchase conveys the research package (data, formulation, patent application,
drawings, scripts) plus worldwide commercialization rights to the
named buyer entity. Patents and underlying IP are retained by
Christopher Gabriel Brown and are NOT sold. Buyer of record must be a
USA entity (up to 4 entities, joint & several). All sales final, non-refundable.
All inquiries by email and postal mail only — no phone calls, no brokers,
no intermediaries.
Parkinson’s Mechanism Analysis
Computational research findings — NOT medical advice, NOT clinically tested, NOT FDA-approved, NOT a cure. A computational discovery of the elemental signatures involved in Parkinson’s biology — the strongest of the three packages, with one direction (NAC/glutathione) backed by actual human PD trial data, plus a genuinely novel compound class. Supplement-grade research; not a replacement for prescribed PD medication.
| Product | Licensed Research: Parkinson’s Mechanism Analysis |
| System | Alchemy Data V2 — 29 elemental signatures identified |
| Strongest direction | NAC / glutathione (C-H-O-N-S) — human DaTscan data |
| IP posture | Patent application #19/445,644, Patent Pending |
| License fee | $42,500.00 USD — Licensed transfer |
New companion: see where this sits on the real FDA approval road — The Parkinson’s Discovery on the Real FDA Road explains what it would take to turn this into an approved medicine, and the one lawful way to make it as a dietary supplement. Available in the same category: cri-one.com/store/licensed-research.html.
01 Top discoveries — evidence graded
| Compound | Grade | Key role |
| C-H-O-N (base organic) | A | L-DOPA — the gold-standard PD drug — belongs to this class |
| C-H-O-N-S (sulfur amino acids) | A (human PD trials) | NAC increased dopamine-transporter binding on DaTscan; GSH depletion is an early PD marker |
| C-H-O-N-Mg (magnesium) | B+ | NMDA antagonism; muscle-rigidity support; PD risk association |
| C-H-O-N-S-Zn (zinc-cysteine) | B+ | Metallothionein neuroprotection; MT-I/II protect against MPTP |
| C-H-O-N-Zn-F/I/Br/Cl (zinc-halogens) | NOVEL — zero data | Genuinely original prediction; requires laboratory investigation; excluded from the formula |
| C-H-O-N-Fe (iron) | A (ID) / harmful | Tyrosine-hydroxylase cofactor BUT accumulation drives ferroptosis — excluded |
02 Strongest evidence — NAC / glutathione (human PD data)
- Monti et al. 2019 (PMID 31048906) — DaTscan SPECT showed significant increases in dopamine-transporter binding (caudate & putamen) after NAC.
- Coles et al. 2018 (PMID 29304084) — MR spectroscopy confirmed NAC increases brain glutathione in PD patients.
- Monti et al. 2016 (PMID 27708942) — NAC improved blood antioxidant measures (GSH/GSSG).
- Sian 1994 (PMID 8210224) — GSH depletion in the substantia nigra is one of the earliest detectable PD changes.
03 Novel discovery & metal context
- Zinc-halogen amino acids (Zn-F / Zn-I / Zn-Br / Zn-Cl): unique to the Parkinson’s output, with zero published research on these classes in neurodegeneration. Excluded from the practical formula pending safety/efficacy research.
- Iron and copper are dopamine-synthesis cofactors but accumulate pathologically in the PD substantia nigra — iron is EXCLUDED.
- Zinc is kept LOW (15 mg) to support BDNF while minimizing alpha-synuclein aggregation risk.
04 What is in the package
- Discovery data (JSON) — compounds with probability scores and pathways.
- Known-properties report (peer-review corrected, evidence-graded).
- 30-day formula with pharmacist compounding specs (CAS numbers, USP-grade forms, interactions).
- Patent application + four patent drawings (SVG); USPTO forms list.
- Discovery script for reproducing and extending the research.
Research disclaimer. These are research discoveries, NOT proven cures. While NAC has human PD trial data showing dopamine-transporter improvements, these were small studies and NAC is not an FDA-approved PD treatment. Iron and copper supplementation would likely worsen disease. Supplement-grade formulations, not pharmaceutical drugs, and not replacements for prescribed PD medications (levodopa, dopamine agonists, MAO-B inhibitors).
Inquiries
Christopher Gabriel Brown — Inventor & Licensor
Email and postal mail only — no phone calls, no brokers, no intermediaries.
crioneaka@outlook.com ·
1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA
crioneaka@outlook.com ·
1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA
Educational only. Not medical, legal, or regulatory advice; not a claim that any compound is a cure; not affiliated with or endorsed by the FDA or USPTO. Supplement-grade research, not an FDA-approved drug. Do not self-treat; consult a licensed physician. USA buyers only; sales subject to Georgia (Gwinnett County) law.
© 2026 Christopher Gabriel Brown. All rights reserved. “Cri-One” and “Licensed Research” are product designations of the licensor. Patents retained; not sold.
Write Your Own Review
Related Products
Check items to add to the cart or
